Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Executes Amendment to Agreement with Quest

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian genetics testing firm Genetic Technologies today said today it has executed an amendment to the Non-Coding License Agreement issued to Quest Diagnostics in 2003.

The amendment extends the terms of the Quest's original non-coding license to "regularize Quest's historical" worldwide activities related to its genetic diagnostic and analysis products. Terms of the agreement were not disclosed.

In a statement, Genetic Technologies said that Quest is not a defendant in Genetic Technologies' US patent infringement suit filed in February against several firms.

"These licenses are a material source of non-dilutive funding which the company is using to build its global oncology franchise," Paul MacLeman, CEO of Genetic Technologies, said in a statement.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.